1h Free Analyst Time
The publisher's latest Pharmaceutical and Healthcare disease pipeline guide Radiodermatitis - Drugs In Development, 2022, provides an overview of the Radiodermatitis (Toxicology) pipeline landscape.Speak directly to the analyst to clarify any post sales queries you may have.
Radiodermatitis is an inflammation of the skin caused by radiation. Several factors can be attributed to the varying response of patients' skin to radiation therapy such as treatment-related factors such as individual fraction size, type of energy, and the use of bolus doses can impact skin reactions. Host factors also may play a role in the development of radiodermatitis; they include genetic factors, personal factors, existing skin integrity issues, comorbid conditions, nutritional status, age, race and ethnicity, medications, sun exposure, smoking, and mobility.
Report Highlights
The publisher's Pharmaceutical and Healthcare latest pipeline guide Radiodermatitis - Drugs In Development, 2022, provides comprehensive information on the therapeutics under development for Radiodermatitis (Toxicology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.The Radiodermatitis (Toxicology) pipeline guide also reviews of key players involved in therapeutic development for Radiodermatitis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Phase II, Phase I, Preclinical and Discovery stages are 4, 3, 10 and 1 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 1 molecules, respectively.
Radiodermatitis (Toxicology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from the publisher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
Scope
- The pipeline guide provides a snapshot of the global therapeutic landscape of Radiodermatitis (Toxicology).
- The pipeline guide reviews pipeline therapeutics for Radiodermatitis (Toxicology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Radiodermatitis (Toxicology) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Radiodermatitis (Toxicology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Radiodermatitis (Toxicology)
Reasons to Buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Radiodermatitis (Toxicology).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Radiodermatitis (Toxicology) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents
- Introduction
- Report Coverage
- Radiodermatitis - Overview
- Radiodermatitis - Therapeutics Development
- Pipeline Overview
- Pipeline by Companies
- Pipeline by Universities/Institutes
- Products under Development by Companies
- Products under Development by Universities/Institutes
- Radiodermatitis - Therapeutics Assessment
- Assessment by Target
- Assessment by Mechanism of Action
- Assessment by Route of Administration
- Assessment by Molecule Type
- Radiodermatitis - Companies Involved in Therapeutics Development
- Allander Biotechnologies LLC
- Amryt Pharma Plc
- BioCurity Pharmaceuticals Inc
- Clevexel Pharma SA
- Devonian Health Group Inc
- Enveric Biosciences Inc
- Foresee Pharmaceuticals Co Ltd
- Lutris Pharma
- Matrix Biomed Inc
- Neuropathix Inc
- Noveome Biotherapeutics Inc
- Perpetuum BV
- Regeneus Ltd
- RepoCeuticals ApS
- Sunny Pharmtech Inc
- VasoDynamics Ltd
- Radiodermatitis - Drug Profiles
- Biologic for Radiodermatitis - Drug Profile
- Product Description
- Mechanism Of Action
- birch triterpenes - Drug Profile
- Product Description
- Mechanism Of Action
- cannabidiol - Drug Profile
- Product Description
- Mechanism Of Action
- cerium oxide - Drug Profile
- Product Description
- Mechanism Of Action
- CVXL-0095 - Drug Profile
- Product Description
- Mechanism Of Action
- Drugs for Enteritis, Proctitis, Pulmonary Inflammation, Radiodermatitis, Xerostomia And Oncology - Drug Profile
- Product Description
- Mechanism Of Action
- FP-045 - Drug Profile
- Product Description
- Mechanism Of Action
- KLS-13019 - Drug Profile
- Product Description
- Mechanism Of Action
- LUT-014 - Drug Profile
- Product Description
- Mechanism Of Action
- melatonin - Drug Profile
- Product Description
- Mechanism Of Action
- NG-121 - Drug Profile
- Product Description
- Mechanism Of Action
- NG-122 - Drug Profile
- Product Description
- Mechanism Of Action
- PCSMD-05 - Drug Profile
- Product Description
- Mechanism Of Action
- phenylbutyrate - Drug Profile
- Product Description
- Mechanism Of Action
- PUR-0110 - Drug Profile
- Product Description
- Mechanism Of Action
- ST-266 - Drug Profile
- Product Description
- Mechanism Of Action
- Sygenus - Drug Profile
- Product Description
- Mechanism Of Action
- Tempol - Drug Profile
- Product Description
- Mechanism Of Action
- ZM-241385 - Drug Profile
- Product Description
- Mechanism Of Action
- Radiodermatitis - Dormant Projects
- Radiodermatitis - Discontinued Products
- Radiodermatitis - Product Development Milestones
- Featured News & Press Releases
- Nov 18, 2021: Enveric Biosciences announces positive preclinical data for EV102 Radiodermatitis Drug Candidate
- Jul 20, 2021: Neuropathix announces publication of PCT patent application for the treatment of radiation dermatitis and other skin disorders
- Sep 24, 2020: Allander Biotechnologies announces NIH Small Business Innovation Research phase II funding
- Jul 29, 2020: Jay Pharma to file IND applications to FDA for a clinical study of proprietary formulations in Radiodermatitis and a combination therapy in glioblastoma
- Dec 11, 2019: Kannalife announces filing of U.S. Patent 62/934,861 - Functionalized 1, 3 Benzene Diols and their method of use for the treatment of radiation dermatitis and other skin disorders
- Appendix
- Methodology
- Coverage
- Secondary Research
- Primary Research
- Expert Panel Validation
- Contact Us
- Disclaimer
- Number of Products under Development for Radiodermatitis, 2022
- Number of Products under Development by Companies, 2022
- Number of Products under Development by Universities/Institutes, 2022
- Products under Development by Companies, 2022
- Products under Development by Universities/Institutes, 2022
- Number of Products by Stage and Target, 2022
- Number of Products by Stage and Mechanism of Action, 2022
- Number of Products by Stage and Route of Administration, 2022
- Number of Products by Stage and Molecule Type, 2022
- Radiodermatitis - Dormant Projects, 2022
- Radiodermatitis - Discontinued Products, 2022
- Number of Products under Development for Radiodermatitis, 2022
- Number of Products under Development by Companies, 2022
- Number of Products by Top 10 Targets, 2022
- Number of Products by Stage and Top 10 Targets, 2022
- Number of Products by Top 10 Mechanism of Actions, 2022
- Number of Products by Stage and Top 10 Mechanism of Actions, 2022
- Number of Products by Top 10 Routes of Administration, 2022
- Number of Products by Stage and Top 10 Routes of Administration, 2022
- Number of Products by Top 10 Molecule Types, 2022
- Number of Products by Stage and Top 10 Molecule Types, 2022
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- Allander Biotechnologies LLC
- Amryt Pharma Plc
- BioCurity Pharmaceuticals Inc
- Clevexel Pharma SA
- Devonian Health Group Inc
- Enveric Biosciences Inc
- Foresee Pharmaceuticals Co Ltd
- Lutris Pharma
- Matrix Biomed Inc
- Neuropathix Inc
- Noveome Biotherapeutics Inc
- Perpetuum BV
- Regeneus Ltd
- RepoCeuticals ApS
- Sunny Pharmtech Inc
- VasoDynamics Ltd
